Loading
A phase 2/3 trial of Margetuximab, Retifanlimab and Trastuzumab in HER2-positive gastric cancer, run by MacroGenics, completed.
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer is a phase 2/3 interventional study registered as NCT04082364 by MacroGenics, with 82 participants recorded, started 2019-09-30 and reaching its primary completion in 2024-01-15. Interventions recorded: margetuximab, Retifanlimab, Tebotelimab, Trastuzumab, Chemotherapy. Conditions recorded: Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer.
Linked to the drug Margetuximab because the registry names it among its interventions and HER2-positive gastric cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
82 enrolled.
95% CI 37.2 to 66.7; Figures from the ClinicalTrials.gov results section (first posted 2025-04-22), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) for Non-microsatellite Instability-high (Non-MSI-H) Participants (Cohort A) Using Investigator-assessed Radiology Reviewsprimary | Chemotherapy-free Arm | 48 | 52.1% | - | - | link |
Shares MacroGenics, Margetuximab, Trastuzumab and the tag pipeline.
Shares Margetuximab, Trastuzumab and the tag pipeline.
Shares Retifanlimab and the tag pipeline.
Shares HER2-positive gastric cancer, Trastuzumab and the tag pipeline.
Shares Retifanlimab and the tag pipeline.
Shares HER2-positive gastric cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Trastuzumab and the tag pipeline.
Shares MacroGenics and the tag pipeline.